1887
Rapid communication Open Access
Like 1

Abstract

Three months after a coronavirus disease (COVID-19) outbreak in Kupferzell, Germany, a population-based study (n = 2,203) found no RT-PCR-positives. IgG-ELISA seropositivity with positive virus neutralisation tests was 7.7% (95% confidence interval (CI): 6.5–9.1) and 4.3% with negative neutralisation tests. We estimate 12.0% (95% CI: 10.4–14.0%) infected adults (24.5% asymptomatic), six times more than notified. Full hotspot containment confirms the effectiveness of prompt protection measures. However, 88% naïve adults are still at high COVID-19 risk.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2020.25.47.2001752
2020-11-26
2021-07-25
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2020.25.47.2001752
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/25/47/eurosurv-25-47-2.html?itemId=/content/10.2807/1560-7917.ES.2020.25.47.2001752&mimeType=html&fmt=ahah

References

  1. Santos-Hövener C, Busch MA, Koschollek C, Schlaud M, Hoebel J, Hoffmann R, et al. Seroepidemiologische Studie zur Verbreitung von SARS-CoV-2 in der Bevölkerung an besonders betroffenen Orten in Deutschland – Studienprotokoll von CORONA-MONITORING lokal. Journal of Health Monitoring.2020;5(S5):2-18.
  2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.  https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045  PMID: 31992387 
  3. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465-9.  https://doi.org/10.1038/s41586-020-2196-x  PMID: 32235945 
  4. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. Am J Epidemiol. 1978;107(1):71-6.  https://doi.org/10.1093/oxfordjournals.aje.a112510  PMID: 623091 
  5. Oved K, Olmer L, Shemer-Avni Y, Wolf T, Supino-Rosin L, Prajgrod G, et al. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation. EClinicalMedicine. 2020;100651.
  6. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085-7.  https://doi.org/10.1056/NEJMc2025179  PMID: 32706954 
  7. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598-607.  https://doi.org/10.1038/s41564-020-00813-8  PMID: 33106674 
  8. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845-8.  https://doi.org/10.1038/s41591-020-0897-1  PMID: 32350462 
  9. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al. Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure. medRxiv. 2020;2020.08.14.20174490. Available from: https://www.medrxiv.org/content/10.1101/2020.08.14.20174490v1
  10. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-4.  https://doi.org/10.1038/s41591-020-0965-6  PMID: 32555424 
  11. Weis S, Scherag A, Baier M, Kiehntopf M, Kamradt T, Kolanos S, et al. Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study. medRxiv. 2020;2020.07.15.20154112. Available from: https://www.medrxiv.org/content/10.1101/2020.07.15.20154112v1
  12. Poethko-Müller C, Prütz F, Buttmann-Schweiger N, Fiebig J, Sarganas G, Seeling S, et al. Studien zur Seroprävalenz von SARS-CoV-2 in Deutschland und international. Journal of Health Monitoring.2020;5(S4):2-16.
  13. Streeck H, Schulte B, Kümmerer BM, Richter E, Höller T, Fuhrmann C, et al. Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nat Commun. 2020;11(1):5829.  https://doi.org/10.1038/s41467-020-19509-y  PMID: 33203887 
  14. Aziz NA, Corman VM, Echterhoff AKC, Richter A, Schmandke A, Schmidt ML, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany. medRxiv. 2020;2020.08.24.20181206. Available from: https://www.medrxiv.org/content/10.1101/2020.08.24.20181206v1
  15. Knabl L, Mitra T, Kimpel J, Roessler A, Volland A, Walser A, et al. High SARS-CoV-2 Seroprevalence in Children and Adults in the Austrian Ski Resort Ischgl. medRxiv. 2020;2020.08.20.20178533. Available from: https://www.medrxiv.org/content/10.1101/2020.08.20.20178533v
  16. Percivalle E, Cambiè G, Cassaniti I, Nepita EV, Maserati R, Ferrari A, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Euro Surveill. 2020;25(24).  https://doi.org/10.2807/1560-7917.ES.2020.25.24.2001031  PMID: 32583766 
  17. Chen X, Chen Z, Azman AS, Deng X, Chen X, Lu W, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. medRxiv. 2020;2020.09.11.20192773. Available from: https://www.medrxiv.org/content/10.1101/2020.09.11.20192773v2
  18. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724-34.  https://doi.org/10.1056/NEJMoa2026116  PMID: 32871063 
  19. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020;2020.03.30.20047365. Available from: https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v2
  20. Wang X, Guo X, Xin Q, Pan Y, Li J, Chu Y, et al. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. medRxiv. 2020;2020.04.15.20065623. Available from: https://www.medrxiv.org/content/10.1101/2020.04.15.20065623v3
  21. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. , ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535-44.  https://doi.org/10.1016/S0140-6736(20)31483-5  PMID: 32645347 
  22. Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann Epidemiol. 2020;48:23-29.e4.  https://doi.org/10.1016/j.annepidem.2020.06.004  PMID: 32648546 
  23. Houlihan CF, Beale R. The complexities of SARS-CoV-2 serology. Lancet Infect Dis. 2020;S1473-3099(20)30699-X. PMID: 32979317 
/content/10.2807/1560-7917.ES.2020.25.47.2001752
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error